{"schema_version":"1","generated_at":"2026-11-04T12:03:56.806Z","data_as_of":null,"url":"https://www.findmykol.com/kol/gayathri-ravi","json_url":"https://www.findmykol.com/kol/gayathri-ravi/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"gayathri-ravi","name":"Gayathri Ravi","credential":"MD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"city":"Rochester","state":"MN","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1881825412","orcid":"0000-0002-0467-1819","openalex":"A5108566118"},"summary":"Gayathri Ravi is a Hematology physician. OpenAlex indexes 84 publications with 280 citations (h-index 9); ClinicalTrials.gov lists 2 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":84,"cited_by_count":280,"h_index":9,"latest_activity_year":2026,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT07333261","title":"Study of BMS-986453 in Newly Diagnosed Multiple Myeloma","phase":"PHASE1","status":"RECRUITING","role":"Site investigator","sponsor":"Susan Bal","source_url":"https://clinicaltrials.gov/study/NCT07333261","trial_url":"https://www.findmykol.com/trial/NCT07333261"},{"nct":"NCT04991103","title":"Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)","phase":"PHASE2","status":"RECRUITING","role":"Site investigator","sponsor":"University of Alabama at Birmingham","source_url":"https://clinicaltrials.gov/study/NCT04991103","trial_url":"https://www.findmykol.com/trial/NCT04991103"}],"source":"trials"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":6,"shown":3,"withheld":3,"rows":[{"payer":"Janssen","program_year":2025,"amount_usd":302395.66,"payment_count":54,"source_url":"https://openpaymentsdata.cms.gov/search?query=1881825412"},{"payer":"Pfizer","program_year":2025,"amount_usd":18568,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1881825412"},{"payer":"Janssen","program_year":2024,"amount_usd":606422.29,"payment_count":73,"source_url":"https://openpaymentsdata.cms.gov/search?query=1881825412"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1881825412","source":"payments"},"prescribing":{"data_year":2024,"areas_total":9,"areas_shown":3,"areas":[{"area":"Dermatology","share_pct":22.4,"classes_total":2,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":20.9,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":40},{"class":"Corticosteroid","setting":"prescribed","share_pct":1.5,"drugs":[{"name":"Triamcinolone Acetonide","share_pct":100}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":21.5,"classes_total":1,"classes":[{"class":"Thalidomide Analog","setting":"prescribed","share_pct":21.5,"drugs":[{"name":"Lenalidomide","share_pct":73.4},{"name":"Revlimid","share_pct":26.6}],"max_beneficiaries":22}]},{"area":"Anti-infectives","share_pct":15.4,"classes_total":3,"classes":[{"class":"Tetracycline-class Drug","setting":"prescribed","share_pct":9,"drugs":[{"name":"Doxycycline Hyclate","share_pct":84.5},{"name":"Doxycycline Monohydrate","share_pct":15.5}],"max_beneficiaries":null},{"class":"Short-acting sulfonamides","setting":"prescribed","share_pct":3.6,"drugs":[{"name":"Sulfamethoxazole-Trimethoprim","share_pct":100}],"max_beneficiaries":12}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":2.3,"facility_pct":97.7},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy","year":2026,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2025031952","status":"verified"},{"title":"Validation of the 2025 IMS / IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant","year":2026,"journal":"British Journal of Haematology","source_url":"https://doi.org/10.1111/bjh.70359","status":"verified"},{"title":"Redefining functional high‐risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation","year":2026,"journal":"Cancer","source_url":"https://doi.org/10.1002/cncr.70478","status":"verified"},{"title":"Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2024027674","status":"verified"},{"title":"Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma","year":2025,"journal":"Leukemia","source_url":"https://doi.org/10.1038/s41375-025-02518-5","status":"verified"}],"source":"works"},"contact":{"address_1":"200 1ST ST SW","city":"Rochester","state":"MN","zip":"559050001","phone":"507-284-2511","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1881825412","source":"identity"},"similar":[{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"},{"name":"Jaroslaw Maciejewski","slug":"jaroslaw-maciejewski","institution":"Cleveland Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/jaroslaw-maciejewski","json_url":"https://www.findmykol.com/kol/jaroslaw-maciejewski/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":3,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2023-06-28","provider_certified":"2021-11-01","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}